Amy P. Abernethy, MD, PhD

home / authors / amy-p-abernethy-md-phd

Articles

January 17th 2017

An Expanded Portfolio of Survival Metrics for Assessing Anticancer Agents

Jennifer Karweit, MS Srividya Kotapati, PharmD Samuel Wagner, PhD James W. Shaw, PhD, PharmD, MPH Steffan W. Wolfe, BA Amy P. Abernethy, MD, PhD

A novel, simplified cost-value analysis tool was created to better differentiate the value of anticancer agents and further characterize the expected survival benefit of all patients.

September 15th 2015

The Utility of Cost Discussions Between Patients With Cancer and Oncologists

S. Yousuf Zafar, MD, MHS Fumiko Chino, MD Peter A. Ubel, MD Christel Rushing, MS Gregory Samsa, PhD Ivy Altomare, MD Jonathan Nicolla, MBA Deborah Schrag, MD James A. Tulsky, MD Amy P. Abernethy, MD, PhD Jeffery M. Peppercorn, MD, MPH

Many patients with cancer desire cost discussions with doctors, but those discussions are rare. Nevertheless, cost discussions may lower patient costs-usually without altering treatment.